In the assessment of 12-month price targets, analysts unveil insights for Emergent BioSolutions, presenting an average target ...

Emergent BioSolutions (NYSE:EBS – Get Free Report) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Friday. Several other equities ...

Papa presented the company’s “turnaround plan” for 2025 at J.P. Morgan. “We are focused on first stabilising the company, ...

Emergent BioSolutions (NYSE:EBS – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have ...

Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today tha This option is part of Emergent’s existing 10-year contract with BARDA for advanced development and ...

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Emergent Biosolutions (EBS – Research Report), with a ...

During the last three months, 4 analysts shared their evaluations of Emergent BioSolutions (NYSE:EBS), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...

H.C. Wainwright & Co. reaffirmed its Buy rating and $15.00 price target for Emergent BioSolutions stock (NYSE:EBS). The ...

Emergent BioSolutions Inc. is a biopharmaceutical company focused on protecting and enhancing life by developing and manufacturing vaccines and antibody therapeutics that are supplied to ...

Tuesday, H.C. Wainwright & Co. reaffirmed its Buy rating and $15.00 price target for Emergent BioSolutions stock (NYSE:EBS). The endorsement comes after the company announced a significant ...

Emergent BioSolutions Inc. (EBS) stock price is 11.19 and Emergent BioSolutions Inc. (EBS) 10-day simple moving average is 10.22. Emergent BioSolutions Inc. (EBS) stock price is 11.19 and Emergent ...